Baseline and dynamic plasma chromogranin A (CgA) level to predict clinical outcome and tumor response in Asian patients with gastroenteropancreatic neuroendocrine tumor (GEP-NET).

被引：0
|
作者：
Chou, Wen-Chi [1 ]
机构：
[1] Linkou Chang Gung Mem Hosp, Taoyuan, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15151
引用
收藏
页数：1
相关论文
共 39 条
  • [21] Use of Multiple Sources of Electronic Healthcare Record (EHR) Drug Data to Study Somatostatin Analogue (SSA) Dosing for Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Treatment
    Jalbert, Jessica J.
    Meng, Jie
    Brais, Lauren K.
    Dutton, Trevor
    Pulgar, Sonia J.
    Berthon, Anthony
    Gabriel, Sylvie
    Dinet, Jerome
    Kulke, Matthew H.
    Casciano, Roman
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 122 - 122
  • [22] Clinical Analysis of 245 Patients With Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET): A Single-Center Retrospective Study (2002-2013) in South China
    Mo, ZhiHui
    Chen, Ye
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S631 - S631
  • [23] SYMNET: A Study of Patient-Reported Outcomes (PROs) Associated with Lanreotide Autogel (LAN) for the Control of Carcinoid Syndrome (CS) Symptoms in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients (Pts)
    Ruszniewski, P.
    Caplin, M.
    Valle, L.
    Lombard-Bohas, D.
    Poston, G.
    Perros, P.
    Holubec, L.
    Delle Pave, G.
    Smith, D.
    Niccoli, P.
    Maisonobe, P.
    Atlan, P.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 274 - 274
  • [24] Larger Tumor Size and Elevated Serum Chromogranin A Levels Predict Metastatic Disease on DOTATATE Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Labora, Amanda
    Shimizu, Takayuki
    Moore, Alexandra
    Premji, Alykhan
    Armstrong, Wesley R.
    Chen, Kevin Y.
    Link, Jason
    Chan, Charlotte S.
    Allen-Auerbach, Martin S.
    Donahue, Timothy R.
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (10) : 6875 - 6882
  • [25] Tumor response in the CLARINET study of lanreotide depot vs. placebo in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Phan, Alexandria T.
    Dasari, Arvind
    Liyanage, Nilani
    Cox, David
    Lowenthal, Susan Pitman
    Wolin, Edward M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [26] Tumor Response in the CLARINET Study of Lanreotide Depot/Autogel vs Placebo in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (03) : 11 - 12
  • [27] Plasma Protein Kallikrein-14 Strongly Predicts Pronounced Chromogranin A (CgA) Response in Small Intestinal Neuroendocrine Tumor (NET) Patients after Somatostatin Analog (SSA) Treatment: The Nordic EXPLAIN Biomarker Study
    Kjellman, M.
    Knigge, U.
    Welin, S.
    Gronbaek, H.
    Thiis-Evensen, E.
    Sorbye, H.
    Joergensen, M. T.
    Johanson, V
    Si, Metso
    Kj, Becker
    Strom, T.
    Belusa, R.
    NEUROENDOCRINOLOGY, 2018, 106 : 155 - 155
  • [28] ASO Visual Abstract: Larger Tumor Size and Elevated Serum Chromogranin A Levels Predict Metastatic Disease on DOTATATE Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors
    Labora, Amanda
    Shimizu, Takayuki
    Moore, Alexandra
    Premji, Alykhan
    Armstrong, Wesley R.
    Chen, Kevin Y.
    Link, Jason
    Chan, Charlotte S.
    Allen-Aurbach, Martin S.
    Donahue, Timothy R.
    ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (02) : 1197 - 1198
  • [29] Patient-reported satisfaction with symptom control during lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients: Symnet, a large multinational, cross-sectional, observational study
    Ruszniewski, Philippe B.
    Caplin, Martyn E.
    Valle, Juan W.
    Bohas, Catherine Lombard
    Maisonobe, Pascal
    Atlan, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [30] A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients
    Siebinga, Hinke
    de Wit-van der Veen, Berlinda J. J.
    Beijnen, Jos H.
    Dorlo, Thomas P. C.
    Huitema, Alwin D. R.
    Hendrikx, Jeroen J. M. A.
    EJNMMI RESEARCH, 2023, 13 (01)
1234